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Background: To evaluate predictive factors for recovery time from severe ovarian hyperstimulation syndrome (OHSS).
Methods: In a retrospective cohort study, 201 women who were hospitalized for severe OHSS were included. Patients
with recurrent OHSS were excluded. All the patients received standardized treatment including intravenous hydration,
plasma volume expansion, human albumin, furosemid, subcutaneous heparin, and paracentesis if necessary. The
main outcome parameter was recovery time from OHSS. Recovery was defined if a morning hematocrit <40%,
rebalance of electrolytes, and serum creatinine <1 mg/dL were reached during the standardized therapy and
the patient had not suffered from abdominal pain and discomfort at least for one day without any OHSS-specific
infusions or medications.
Results: Pregnant patients (n = 80, 39.8%) revealed a longer median duration until recovery than non-pregnant patients
(n = 121, 60.2%; 10 days, IQR 7-13, vs. 8 days, IQR 6-10, respectively; p = 0.001). In a generalized linear model, presence of
polycystic ovary syndrome before controlled ovarian hyperstimulation (beta = 0.3342 +/- 0.1335, p = 0.012) and use of
hCG for ovulation induction (beta = 0.222 +/- 0.1389, p = 0.048) were associated with a longer recovery time in
pregnant patients. In non-pregnant patients, none of the tested factors was associated with recovery time.
Conclusions: Pregnant patients with severe OHSS needed a significantly longer recovery time than non-pregnant
patients. In pregnant patients, presence of polycystic ovary syndrome and ovulation induction with hCG were
associated with longer recovery times.
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Although in vitro fertilization (IVF) has become a safe and
common approach to infertility treatment, undesired side
effects still remain. Notably, controlled ovarian stimulation
(COH) is the main cause of ovarian hyperstimulation syn-
drome (OHSS).
OHSS is a severe complication caused by COH with
gonadotropins. It is characterized by sudden ovarian en-
largement with multiple cysts, and an acute shift of
intravascular fluid into the third space, leading to ascites,
pleural effusion and hemoconcentration, and increased
blood viscosity [1]. There are different classifications for
OHSS. The most frequently used classification system is* Correspondence: johannes.ott@meduniwien.ac.at
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unless otherwise stated.the classification by Golan [2]. OHSS occurs in a mild
form, which is not of clinical relevance, in up to 30% of
all IVF patients [3]. However, 2-3% of all IVF-patients
present with a clinically relevant disorder. The incidence of
severe OHSS itself is 0.2-1%, which is a life-threatening
situation, due to the above-mentioned consequences [4].
Increased hemoconcentration and blood viscosity can
cause thrombembolic events that might lead to potentially
fatal cardiovascular or neurological events [5]. Although a
number of potentially preventive measures have been pro-
posed, complete prevention, especially of late onset OHSS,
is still not possible [6].
COH using GnRH agonists (“long protocol”) is still the
most commonly used protocol for IVF cycles worldwide.
The mechanism of action is pituitary desensitization with
subsequent gonadotropin suppression. In order to decrease
the risk for OHSS, GnRH agonists were first introducedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(i.e. ovulation induction). Thereby, an actual decrease
in OHSS incidence could be achieved. However, these can
only be used after COH using an antagonist protocol. In
other words, the use of GnRH agonists (“long protocol”)
permits a stronger COH of the ovaries but does not
allow the use of GnRH agonists for triggering the final
follicular maturation. Hence, this results in an increased
incidence of OHSS in patients with long protocol [7-9].
Thus, the use of GnRH antagonists (“antagonist protocol”)
is an alternative to GnRH agonists used in long protocol,
especially in terms of OHSS prevention [10]. Although the
first Cochrane review comparing the two stimulation pro-
tocols did not find significant differences in the incidence
of OHSS [11], more recent meta-analyses clearly demon-
strated that GnRH antagonists were associated with a sig-
nificant reduction in the incidence of severe OHSS and,
thus, the hospitalization rate [12,13]. Nonetheless, the use
of GnRH antagonists does not rule out the development of
severe OHSS [14]. Indeed, when using GnRH agonists as
trigger substances in an antagonist protocol, severe OHSS
still can occur [12-14]. Other factors that increase the risk
for severe OHSS are presence of polycystic ovary syndrome
and a lean body mass [15]. Despite the fact that there is
high-level evidence for risk factors for the development of
OHSS, as mentioned above, there are few studies about its
influence on the course of severe OHSS.
According to recent guidelines, severe OHSS is an in-
dication for hospitalization due to possible life-threatening
complications [16]. Usually, patients are released as soon
as the patient’s condition has improved and is no longer at
high risk. Hence, the time until recovery must be consid-
ered a clinically important parameter. This is of clinical
impact since, from our experience, patients do suffer
decreased quality of life due to OHSS-specific symptoms
as well as hospitalization. Moreover, the duration of
hospitalization is also of economic relevance. Predictive
parameters that would allow assessment of recovery time
would be desirable. We, thus, aimed to examine possible
influencing factors for the recovery time in severe OHSS.
In addition to the type of protocol used for COH and the
substance used for ovulation induction, we also focused
on other possible influencing parameters.
Methods
Patient population
In a retrospective study, all women who underwent
COH for IVF at the Department of Gynecologic Endo-
crinology and Reproductive Medicine of the Medical
University of Vienna, Vienna, Austria, from January 1995
until May 2010, and were hospitalized for severe OHSS,
were included. All OHSS patients with no reliable informa-
tion available about the stimulation protocol were excluded
from the study. This applied only to women who hadundergone COH at another department. In patients who
had suffered from severe OHSS more than once, only the
first hospitalization was included in the analysis. This re-
sulted in a patient population of 201 women. The study
was approved by the ethics committee of the Medical
University of Vienna (IRB number 1184/2012).
Severe OHSS was defined as OHSS grade 3 according
to Golan and Weissman [2]. Women were hospitalized if
they fulfilled at least one criterion of all of the following
three groups of OHSS-specific signs:
(i) presence of clinically relevant symptoms, including
diffuse abdominal discomfort, nausea, vomiting, dyspnea
and tachypnea, subjective decreased urinary output, clin-
ical signs, such as oliguria <600 mL in 24 hours, and/or
hypotension;
(ii) electrolyte imbalance, leukocytosis >20,000/mm3,
serum creatinine >1 mg/dL, and/or hematocrit >45%; and
(iii) sonographically detectable free fluid (ascites and/or
pleural effusion), and a significant increase in ovarian
diameter (>12 cm).
The main outcome parameter was recovery time from
OHSS and discharge from hospital, which was defined
as reaching a morning hematocrit <40%, rebalance of
electrolytes, serum creatinine <1 mg/dL, and that the
patient had not suffered from abdominal pain and dis-
comfort at least for one day without any OHSS-specific
infusions or medications. The above mentioned definition
is included in the treatment protocol at our department.
These are available in written form to all physicians and
they are obliged to adhere to this management scheme.
Standardized OHSS treatment
We obtained a complete blood count with hematocrit,
serum analysis of albumin, blood creatinine, blood urea
and creatinine clearance, liver function parameters, and
coagulation tests on a daily basis in all patients. The
amount of excreted urine, hydric balance, body weight,
and abdominal circumference were carefully checked every
24 hours.
In-patient management included bed rest, hydration
with 1000 ml lactated Ringer’s solution twice a day;
plasma volume expansion with Hydroxyethyl starch so-
lution 6% (HAES-steril® 6% infusion solution, 250 ml
KABI, Homburg, Germany), and human albumin 25%
(Human Albumin® Octapharm, Langfeld, Germany) once
daily in cases of hypoalbuminemia (>34 g/L); and fur-
osemide 20 mg (Lasix® 20 mg, Sanofi, Vienna, Austria),
which was administered intravenously in the above-
mentioned Ringer’s solution twice a day (resulting in a dose
of 40 mg furosemide daily). Paracentesis was performed in
patients with ascites that caused pain or compromised pul-
monary function (e.g., tachypnea, hypoxia, hydrothorax). A
transvaginal approach was used. Directly after the proced-
ure, patients received 100 ml human albumin (see above).
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Prophylactic low-molecular weight heparin therapy (5,000
Units subcutaneously, every 24 hours) was given to all
patients during in-patient treatment. From 2008 on, pa-
tients were treated in accordance with the recom-
mendations set forth by the Practice Committee of the
American Society for Reproductive Medicine in 2008 [1].
In addition to the above mentioned treatment modalities,
patients also received 0.5 mg Cabergoline (Dostinex®,
Pharmacia, Berlin, Germany) orally once a day for ten days
[16] from January 2008. Thus, the inpatient treatment-
regimen had not changed during the observation period,
apart from introduction of Cabergoline.
Patients were observed for one more day without re-
ceiving any infusions or medications when a morning
hematocrit <40% was reached for the first time and were
usually discharged on the next day if the hematocrit
remained <40%. The above mentioned treatment proto-
col was available in written form to all physicians and
they were obliged to adhere to this management scheme,
in case of unclearness a telephone hotline with an IVF
team member was at all times from in 2001.
Parameters analyzed
For the first analysis of predictive factors for duration of
hospitalization, patients were subdivided in non-pregnant
and pregnant patients, since pregnancy is known as a
major risk factor for late onset OHSS and it can worsen
the medical situation of an early onset OHSS [1,17]. All
cases of early onset OHSS that occurred before embryo
transfer all patient that had been hospitalized directly after
embryo transfer and released home within 10 days, i.e.
before a possible rise in serum hCG, were also rated as
“non-pregnant”. Usually, in case of severe OHSS, em-
bryos would get cryoconserved and transferred in the
next cycle. However, in a few cases with low quality of
embryos embryo transfer in the same treatment cycle
was chosen despite OHSS. This was done only after pa-
tients had been informed extensively on their explicit
wish. In the second step that included OHSS-specific pa-
rameters, pregnant and non-pregnant women were not
analyzed separately.
We analyzed the type of stimulation protocol (long
protocol vs. other protocols) and the substance used for
ovulation induction (human chorionic gonadotropin, hCG,
vs. other substances). We also included the type of stimula-
tion protocol as a predictive parameter in addition to the
use of hCG for ovulation induction, since the fact that
GnRH antagonist cycles have a lower risk of OHSS is also
due to differences in follicular recruitment. Accordingly,
even when inducing ovulation with hCG, there is a signifi-
cant reduced risk of OHSS in antagonist cycles as com-
pared to agonist cycles [18]. For agonist triggering, 0.2 mg
Triptorelinacetate (Decapeptyl ®, Ferring, Germany) hadbeen used in patients in danger of developing OHSS in
case of >15 follicles in each ovary.
In addition, we also focused on the following parame-
ters as possible predictive factors for the recovery time:
age; body mass index (BMI); presence of polycystic ovary
syndrome that was known to be associated with a higher
incidence of OHSS [19]; number of retrieved oocytes;
time between oocyte retrieval and hospitalization for
OHSS; whether the patient suffered from early or late
onset OHSS; the use of Cabergoline; and the year the pa-
tient was treated for OHSS (years 1996-2007, i.e. before
the new treatment recommendations [1] were published
and implemented in daily routine at our department vs.
2008-2010, i.e. afterwards) in order to rule out any add-
itional bias due to the introduction of these recommenda-
tions [1] despite the fact that the standardized treatment
regimen had not changed at our department. In the group
of pregnant patients, we also included multiple pregnancies
as a predictive factor. Since standard luteal support in-
cluded only dydrogesterone and/or progesterone supple-
mentation and, in no case, hCG was used for luteal
support, we did not have to evaluate the latter as a predict-
ive factor for recovery time.
In a next step, we also included the following OHSS-
specific parameters in the model: the initial hematocrit
at the time of hospitalization and the maximum hematocrit
seen in the course of regular, daily blood count controls
and the need of paracentesis.
Statistical analysis
Nominal variables are reported as numbers and frequen-
cies, and continuous variables as medians and interquar-
tile ranges (IQR). Statistical analysis was accomplished
using Wilcoxon rank-sum tests where applicable and gen-
eralized linear models with a Poisson link function. For the
latter, coefficient estimates β and eβ, 95%-confidence inter-
val (CI), standard error se(β), and corresponding p-values
are given. Differences between groups were tested using
the ANOVA for numeric variables and the Chi square test
or the Fisher’s exact test for categorical variables where
appropriate. P-values <0.05 were considered statistically
significant. Statistical analyses were performed with the
SPSS software package, version 19 (SPSS, Chicago).
Results
Details about basic patient characteristics are provided in
Table 1. In 156 patients (77.2%), hCG had been used for
ovulation induction (10000 I.E of urinary hCG (Pregnyl ®
Organon, Holland) in 147 cases and 6500 I.E. of recom-
binant hCG (Ovitrel 250 mg ®Merk, UK) in nine cases).
None of the patients had complications such as venous
thrombosis or renal insufficiency. The median recovery
time was 9 days (IQR 7-11 days). Pregnant patients (n = 80,
39.8%) revealed a significantly longer median duration
Table 1 General patient characteristics
Number of patients 201
Age (years)a 30 (26-34)
Body mass index (kg/m2)a 22.4 (20.9-26.1)
Tubal factorb 37 (18.4)
Male factorb 143 (71.1)
Endometriosisb 7 (3.5)
Polycystic ovary syndromeb 19 (9.5)
Idiopathic infertilityb 15 (7.5)
Use of long protocol for controlled ovarian hyperstimulationb 94 (46.5)
Use of hCG for ovulation inductionb 156 (77.2)
Number of retrieved oocytes (n)a 12 (9-17)
Time between oocyte retrieval and hospitalization for OHSS
(days)a
4 (3-8)
Data are provided as amedian (interquartile range) or bn (%).
Multiple citations possible.
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60.2%; 10 days, IQR 7-13, vs. 8 days, IQR 6-10, respectively;
p = 0.001).
In a generalized linear model, we calculated factors
predictive for the recovery time in pregnant patients
(Table 2). Presence of polycystic ovary syndrome before
COH (ß = 0.322 ± 0.1326, p = 0.015) and use of hCG for
ovulation induction (ß = 0.238 ± 0.1373, p = 0.043) were
associated with a longer duration of hospitalization. The




(Intercept) 1.061 0.5915 -0.09
Use of cabergoline -0.182 0.3329 -0.83
Late onset OHSS 0.282 0.2364 -0.18
Polycystic ovary syndrome 0.334 0.1335 0.07
Use of hCG for ovulation induction 0.222 0.1389 0.00
Number of retrieved oocytes (n) 0.015 0.0089 -0.00
Year of COH/OHSS treatment: 1996-2007 0.528 0.3666 -0.19
Use of long protocol 0.053 0.1263 -0.19
Age (years) 0.013 0.0110 -0.00
Body mass index (kg/m2) 0.008 0.0086 -0.00
Multiple pregnancy (n) 0.195 0.1077 -0.01
Time between oocyte retrieval and hospitalization
for OHSS (days)
0.009 0.0180 -0.02
Coefficient estimates β, standard error se(β), 95%-confidence interval (CI) = β ± zα/2
factors are compared to the missing category, i.e., no use of cabergoline, early o
analogues for ovulation induction, year of treatment 2008-2010, controlled ovaria
pregnancy. In the analysis of non-pregnant patients, the parameter “year of treat
parameter “use of long protocol”. Statistically significant p-values are printed in bbetween women with without polycystic ovary syndrome
before (median 11 days, IQR 7-14, vs. median 9 days, IQR
7-12, respectively; p = 0.044) as well as between the types
of ovulation induction (hCG: median 10 days, IQR 8-14,
vs. GnRH agonists: median 9 days, IQR 7-12; p = 0.047).
These results differed from the findings in non-pregnant
patients: in the latter, none of the tested factors was asso-
ciated with the duration of hospitalization (Table 2).
In a next step, we included OHSS-specific parameters
in the generalized linear model (Table 3). At the time of
hospitalization, the initial hematocrit level was 42.3%
(IQR 39.9-45.7). The median maximum hematocrit level
(45.6%, IQR 42.9-47.9) was reached after a median of 1 day
(IQR 1-3; range 1-10). Fifty-one women (25.4%) were in
need for paracentesis due to severe abdominal pain or
compromised pulmonary function. When also including
these OHSS-specific markers into a multivariate model on
all patients, pregnancy (ß = 0.163 ± 0.0756, p = 0.031), pres-
ence of polycystic ovary syndrome (ß = 0.332 ± 0.1065,
p = 0.002), use of hCG for ovulation induction (ß = 1.74 ±
0.0804, p = 0.030), need for paracentesis (ß = 0.446 ±
0.0795, p < 0.001) and both the initial (ß = 0.049 ± 0.0198,
p = 0.013) and maximum hematocrit level (ß = 0.048 ±
0.0200, p = 0.016) were significantly predictive for the
recovery time of OHSS.
Discussion
In this retrospective study, presence of polycystic ovary
syndrome and the use of hCG for ovulation inductionn to predict the recovery time from severe OHSS
ts (n = 80) Non-pregnant patients (n = 121)
95% CI p ß Standard
error (ß)
95% CI p
er Upper Lower Upper
9 2.220 0.073 2.425 0.5608 1.326 3.542 <0.0001
4 0.471 0.585 -0.013 0.0918 -0.193 0.167 0.890
1 0.746 0.233 -0.009 0.2914 -0.580 0.562 0.976
3 0.596 0.012 -0.025 0.1528 -0.274 0.325 0.868
2 0.495 0.048 0.015 0.0941 -0.169 0.200 0.872
2 0.033 0.084 0.004 0.0072 -0.010 0.018 0.603
0 1.247 0.149 -0.071 0.0984 -0.261 0.128 0.482
4 0.301 0.673 -0.047 0.1014 -0.246 0.151 0.641
8 0.035 0.230 -0.003 0.0088 -0.020 0.014 0.740
9 0.025 0.360 -0.006 0.0102 -0.026 0.014 0.585
6 0.406 0.060 - - - - -
7 0.044 0.636 -0.020 0.0212 -0.061 0.022 0.353
se(β), and corresponding p-value are summarized in the table. The categorical
nset OHSS, no polycystic ovary syndrome, use of other substances than hCG
n hyperstimulation with other protocols than long protocol, and no multiple
ment” had to be excluded for this analysis, since it was redundant to the
old numbers.






(Intercept) 1.758 0.5485 0.683 2.833 0.001
Pregnancy 0.163 0.0756 0.015 0.312 0.031
Use of dostinex -0.490 0.3169 -1.111 0.131 0.122
Early (vs. late) onset OHSS 0.206 0.1785 -0.144 0.555 0.249
Polycystic ovary syndrome 0.332 0.1065 0.124 0.541 0.002
Use of long protocol 0.051 0.0753 -0.096 0.199 0.497
Number of retrieved oocytes (n) 0.003 0.0056 -0.008 0.018 0.630
Year of COH/OHSS treatment: 1996-2007 0.655 0.3262 -0.115 1.294 0.065
Use of hCG for ovulation induction 0.174 0.0804 -0.017 0.332 0.030
Age 0.005 0.0065 -0.008 0.018 0.422
BMI 0.010 0.0069 -0.004 0.023 0.159
Time between oocyte retrieval and hospitalization for OHSS (days) -0.005 0.0137 -0.032 0.022 0.696
Necessity for paracentesis 0.446 0.0795 0.290 0.602 <0.001
Initial hematocrit (%) 0.049 0.0198 0.010 0.088 0.013
Maximum hematocrit (%) 0.048 0.0200 0.009 0.088 0.016
Coefficient estimates β, standard error se(β), 95%-confidence interval (CI) = β ± zα/2 se(β) , and corresponding p-value are summarized in the table. The categorical
factors are compared to the missing category, i.e., no use of cabergoline, early onset OHSS, no polycystic ovary syndrome, use of other substances than hCG
analogues for ovulation induction, year of treatment 2008-2010, controlled ovarian hyperstimulation with other protocols than long protocol, and no need for
paracentesis. Statistically significant p-values are printed in bold numbers.
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recovery time in pregnant patients with severe OHSS.
Notably, none of the tested parameters was predictive
for the duration of recovery in non-pregnant patients. In
our data set, the median recovery time was nine days. Of
course, this is dependent on the definition of recovery.
In our study, recovery was defined when a hematocrit
of <40%, electrolyte balance, a normal leucocyte count
and serum creatinine <1 mg/dl were reached, patients
did not suffer any longer from clinically relevant symp-
toms and this situation persisted after one day without
any OHSS-specific treatment. One might consider these
criteria strict since a hematocrit >45% defines severe
OHSS of grade 3 [2]. We consider the a hematocrit cut-
off of 45% for the definition of OHSS recovery as not
useful, since the definition of severe OHSS is not based
on hematocrit alone and many patients do not reveal
hematocrit levels >45% at the time at diagnosis. This is also
in accordance with our results (median initial hematocrit
42.3%, median maximum hematocrit level 45.6%). To date,
an exact definition of recovery has not been provided in
the literature. For example, in their 2008 recommenda-
tions, the Practice Committee of the American Society for
Reproductive Medicine only stated that “serial clinical and
laboratory evaluations provide the means to recognize evi-
dence of resolution”, but do not focus on recovery any fur-
ther [1]. In addition, there is also a lack of data on recovery
time from severe OHSS in the literature.As demonstrated in Table 2, presence of PCOS was a
significant factor predictive of recovery time in pregnant
patients. PCOS is a well-known risk factor for the devel-
opment of OHSS [15,17]. It is noteworthy that, in our
patient population, it also extended the course of severe
OHSS by a median of two days.
The second predictive factor in these patients was the
use of hCG for ovulation induction. Traditionally, in
COS, hCG is administered as a surrogate for the natural
LH surge to induce final oocyte maturation. Since hCG
has a longer half life compared with LH, it has been hy-
pothesized that it could extend the luteinizing stimulus
for the granulosa cells and, thereby, could play a crucial
role in the development of OHSS [19]. While the
luteinizing stimulus exerted by exogenous hCG is the
major driving force behind early OHSS that starts within
eight days after oocyte retrieval, late OHSS seems to be
triggered by endogenous. In case that a patient is at an in-
creased risk of OHSS, withholding the administration of
hCG and aborting the cycle of COH can prevent the pa-
tient from either form of the syndrome [20].
More recently, the use of a GnRH agonist instead
of hCG for ovulation induction has been proposed as
a preventive method to avoid the appearance of OHSS.
The limitation of this measure is the fact that it can only
be achieved in COS cycles in which a GnRH antagonist is
used for pituitary suppression. GnRH agonists used in this
context would have two functions: first, inducing final
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agent and thereby preventing the secretion of vaso-
active substances, namely Vascular Endothelial Growth
Factor (VEGF) from corpora lutea [21]. Our data support
this finding and could also demonstrate that in pregnant
women who suffered from severe OHSS, the use of hCG
as a trigger substance for final follicular maturation was
associated with a longer recovery time, extending it by a
median of one day.
Notably, the type of stimulation protocol was not pre-
dictive for recovery time. This is somehow in line with
the fact that, concerning the development of OHSS,
(i) the use of GnRH agonists for ovulation induction after
COH with an antagonist protocol can prevent the patient
from OHSS and (ii) that the use of a “long protocol” leads
more likely to OHSS since ovulation cannot be induced
with the “low-risk substances”, i.e. GnRH agonists [19-21].
Accordingly, the substance used for ovulation induction is
of a higher overall impact than the stimulation protocol it-
self and this also seems to be the case for the duration of
severe OHSS.
In this study, we confirm that PCOS and hCG are
significant contributors to severe OHSS. Notably, in
non-pregnant patients, neither presence of PCOS and
ovulation induction with hCG nor the other patient-
and IVF-related factors were predictive for the duration
of hospitalization. One has to take into account that
pregnancy is the main factor for late onset OHSS and
that the pregnancy rate is higher in patients with fresh
embryo transfer after hCG compared to GnRH agonist
triggering. This likely contributes to the differences in
predictive factors for duration of OHSS.
As recently reviewed, pregnancy substantially increases
the risk for OHSS and this is thought to be due to an in-
crease in endogenous hCG [17]. Vascular endothelial
growth factor (VEGF) has been identified as the major me-
diator of OHSS [17]. With the exogenous administration
of hCG, the expression of VEGF increases significantly and
the maximum rise coincides with peaked vascular perme-
ability [22]. Hypothetically spoken, assuming that ovulation
induction with hCG would only be a short term stimulus
for VEGF expression in non-pregnant patients, the absence
of a predictive value of hCG administration for OHSS re-
covery time in these women seems reasonable. In other
words, the endogenous hCG production in pregnant OHSS
patients could sustain VEGF expression that had initially
been increased with administration of hCG for ovulation
induction. In addition, increased VEGF levels have been
documented in women with PCOS [23,24]. One could
hypothesize that this might have contributed to the pro-
longed recovery time from OHSS in patients with PCOS.
However, this remains completely speculative.
It should be emphasized that only women who already
suffered from severe OHSS were included in our analysis.This might contribute to the fact that other parameters
that are known to influence the incidence of severe
OHSS such as the time interval between stimulation
and onset of OHSS (late vs. early OHSS) were not asso-
ciated with recovery time [25,26]. Another notable result
of our study was the fact that the introduction of Cabergo-
line treatment did not lead to a significant reduction in re-
covery times from severe OHSS. Recently, it has been
suggested that the use of dopamine agonists appeared to
be effective for the prevention of OHSS, but was less
effective for the treatment of OHSS [27,28]. We, however,
present only non-randomized data. Notably, the OHSS-
specific parameters higher initial and maximum hematocrit
levels as well as the patients’ need for paracentesis were
also reliably predictive for longer recovery times (Table 3)
and, thus, can also be used to assess recovery time in an in-
dividual patient.
One might argue that diuretics such as furosemide are
actually contraindicated in OHSS patients due to known
intravascular volume depletion. Hypothetically spoken,
in case of OHSS, furosemide could put the patient at
risk for further hemoconcentration. However, it also of-
fers the advantage of preventing oliguria/anuria, which is
also a feared complication of OHSS. Therefore we sug-
gest using furosemide only after having started with the
correction of intravascular volume and rehydration of
the OHSS patient. The latter is guaranteed in our treat-
ment regimen, since furosemide is only administered in
combination with 2,000 ml of intravenous saline infusion/
day. In contrast to the recommendations of Alper et al.,
we do not recommend reduction of oral fluid intake to
the patients [29]. One might say that our aim is to reach
both a high volume of fluid in- and output. We do this
in order to correct intravascular hemoconcentration and
also prevent renal failure. We are also aware of the rec-
ommendation to use furosemide only after the hematocrit
level has decreased to 38% or lower (1). However, there
was no case of thromboembolism and also no case of
renal insufficiency in our study population over a long
period of 15 years. Thus, we consider our regimen includ-
ing routine furosemide treatment safe. In addition to these
considerations, we hazarded the hypothetical consequences
of the fact that furosemide is a FDA category C drug which
means that risk cannot be ruled out during pregnancy.
The retrospective study design, our specific definition
of OHSS recovery and the treatment including furosem-
ide have to be considered limitations of this report. In
order to guarantee sound data it is of high relevance that
the decision on patients’ discharge was based on the same
criteria by all the doctors. This might have been a clinical
problem, since on weekends doctors from other divisions
within the Department of Obstetrics and Gynecology were
on duty. Therefore, a telephone hotline with an IVF team
member available for questions regarding OHSS patients
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confident that the management was consistent even on
weekends and public holidays, at least since 2001. One
might wonder why PCOS patients, known to be at a high
risk for OHSS, had been stimulated using a GNRH agonist
protocol. This was the case only in the early years of this
historic patient population (i.e. 1995-2010), since the so
called long protocol had been the dominating treatment
in this time period. Moreover, we consider that the type
of administered hCG (urinary versus recombinant) might
have also influenced the duration of OHSS. However, due
to the small number of cases with recombinant hCG, we
could not analyse this factor separately. One also has to
consider that, in the initial study period, cabergoline had
not been given as a primary prophylactic treatment for
women at risk for OHSS. We cannot rule out that caber-
goline use versus non-use may have affected the charac-
teristics of the study population. In this regard, it is
possible that cabergoline use, which is a physician choice,
could have affected population characteristics such as age
or BMI. This might also be a study limitation. Nonethe-
less, this is the first study to evaluate the factors that
influence the recovery time from severe OHSS. We
are aware of the fact that our study does not add to the
knowledge about prevention of OHSS. We, nonethe-
less, consider it of interest to learn about predictive fac-
tors for recovery time due to its economic and also
medical implications.
Discharge from hospital is dependent on the patients’
condition and, thus, on improvement of OHSS symp-
toms. OHSS patients are only released from hospital
when they are no longer at high risk. It is obvious that
during the time of hospitalisation patients experience
decreased quality of life due to OHSS-specific symptoms
and treatment which may also include repeated paracen-
tesis. Hence, the time until recovery must be considered
a clinically important parameter. Moreover, the duration
of hospitalization likely is of economic relevance. Our
study provides (i) a definition of recovery from OHSS
for the first time; (ii) parameters that predict recovery
time from OHSS which might facilitate counselling of
patients who usually wish for their release home; and
(iii) we share our 15-year experience with our manage-
ment of severe OHSS.
Conclusions
Notably, only in pregnant patients, presence of PCOS
and ovulation induction with hCG were found to have
led to longer recovery times. OHSS-specific parameters
allow a more reliable prediction of recovery time. Fur-
ther studies that focus on recovery to confirm our results
are warranted. In addition, a consensus on the definition
of OHSS recovery would be desirable, probably not only
from a clinical, but also from a forensic point of view.Competing interests
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